Insight

Inflation Reduction Act impact on biopharma portfolio strategies

An examination of potential implications for how drug manufacturers manage their portfolios in the wake of the Inflation Reduction Act

Within healthcare, the Inflation Reduction Act (IRA) aims to improve affordability and accessibility by lowering prescription drug prices and out-of-pocket costs for Medicare beneficiaries and extending premium subsidies in the Affordable Care Act’s (ACA) marketplaces.

Sweeping proposals introduced by the act represent some of the most significant healthcare legislation since the ACA by giving Medicare the ability to negotiate drug prices with manufacturers. In this paper, we discuss potential implications of these policies for how drug manufacturers manage their portfolios.

Contact us

Jeff Stoll, PhD

Jeff Stoll, PhD

Principal, National Strategy Life Sciences Leader, KPMG US

+1 857-334-8768
Ryan Clements

Ryan Clements

Advisory Managing Director Strategy - PDT, KPMG US

+1 617-893-1441
Varun Renjen, MD

Varun Renjen, MD

Managing Director, Life Sciences Deal Advisory and Strategy, KPMG US

+1 973-467-9650
Siu Ping Ngok

Siu Ping Ngok

Director, Advisory, Strategy - PDT, KPMG US

+1 415-963-5100

Related content


KPMG Healthcare & Life Sciences Institute

Register to receive timely insights

Register to receive timely insights

About Healthcare & Life Sciences at KPMG

Our practice

Learn more


Our capabilities

Learn more


Meet our team

Learn more